CELZ

Creative Medical Technology Holdings, Inc. (CELZ) ESG Analysis Analysis (2026)

Invetso Score: 5.2/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Environmental

Score: 5.2 (Moderate)

CELZ appears to have limited environmental disclosure and no evident peer-leading climate or resource-management program, leaving its positioning broadly in line with small-cap biotech peers.

The very high R&D intensity relative to revenue suggests a research-heavy operating model, but this is typical for development-stage biotech and does not create a clear environmental advantage.

No material environmental controversies or regulatory breaches are evident in the provided information, which avoids a peer-relative penalty but does not indicate stronger environmental stewardship.

The absence of leverage-driven industrial footprint or manufacturing intensity reduces direct emissions exposure versus more asset-heavy peers, though this is a structural sector feature rather than a differentiated ESG strength.

Social

Score:

CELZ’s social profile is constrained by limited public evidence of workforce, patient, or community programs, which leaves it behind better-disclosed peers on stakeholder transparency.

The company’s development-stage model can support a science-focused mission, but the provided data do not show peer-leading clinical, safety, or access practices.

Zero stock-based compensation in the supplied metrics may indicate lower dilution-related alignment concerns, yet it does not materially improve broader employee or governance-related social positioning.

No major social controversies are indicated in the available information, but the lack of disclosed social metrics prevents a stronger relative assessment versus more transparent peers.

Governance

Score:

Governance positioning is weakened by the absence of visible disclosure on board independence, audit rigor, and shareholder protections, which is a disadvantage versus better-governed peers.

The reported zero debt-to-equity ratio reduces creditor complexity, but it does not offset the governance uncertainty created by limited transparency and sparse control disclosures.

The extremely high R&D-to-revenue ratio and negative gross margin underscore a capital-dependent model, increasing the importance of disciplined oversight relative to peers.

No severe governance failure is evident in the provided data, but the lack of robust disclosure keeps CELZ below stronger peer governance standards.

Overall Score

Score:

CELZ’s ESG positioning is broadly average to slightly below peers because limited disclosure and weak governance transparency outweigh the absence of major controversies.

Score Driver: Limited ESG Disclosure And Governance Transparency Relative To Peers

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Creative Medical Technology Holdings, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →